- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00802152
Using Health Information Technology (HIT) to Improve Ambulatory Chronic Disease Care: Smart Device Substudy
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
To evaluate the effectiveness of short-term targeted use of remote data transmission from in-home devices (blood glucose meter/blood pressure machine) to the clinic on treatment outcomes in patients with diabetes who have out of range blood glucose (BG) or systolic blood pressure (BP) measurements. Increased frequency of data transmission will provide the provider with "real time" data in order to make more timely adjustments in the treatment plan, resulting in improved glycemic control as measured by A1c values and hypertension as measured by systolic blood pressure (SBP).
Subjects will be recruited from Family & Community Medicine (FCM) and General Internal Medicine (GIM) clinics. We will randomly select patients from physicians with a minimum number of 5 eligible patients from the performance measurement list (A1c>=8% or SBP>130) to approach for the study. Patients who agree to enroll will be randomized to experimental and control using a block randomization approach stratified by age increments (18-40; 41-55; 56-70; 71+). Subjects will be randomized using prepared sealed envelopes. A total of 200 subjects (100 intervention subjects and 100 control subjects) will be enrolled over a period of one year. We will attempt to enroll equal numbers of FCM and GIM subjects.
For all subjects, baseline data will be collected from the patient, including demographic data (age, gender, race, and years of formal education), payor status (private pay, insurance, Medicaid), number of co-morbid conditions, baseline blood pressure, and length of time diagnosed with diabetes (DM) and hypertension.
Intervention patients will be instructed to test their BP and BG according to a minimum protocol of at least once daily and upload this clinical data at least every other day for the 3-month study duration, but this frequency could be further tailored by their provider, i.e., more than once daily. At least 2 of these BG readings each week should be fasting levels. Patient training will emphasize that this system is not an emergency response system, i.e., critical values should be treated in the usual manner.
Control group patients (those who do not receive the device) will be asked to test their BP and BG at least once daily (in the same fashion as the intervention group). They will be instructed to bring these readings to their clinic visits, and again at the end of the study. We will collect these readings.
Data from patients are downloaded to the website as they enter data. These data may be printed out for MD review or verbally communicated. APNs in FCM will make changes in patient treatment based on their currently established privileges, e.g., medication adjustments; RNs in GIM or FCM will review data with MDs for changes in treatment plans. All treatment changes will be individualized according to patient need, i.e., no standardized blood glucose management protocol will be employed. Communication of changes in therapy to the patient will be accomplished per usual clinic protocol, e.g., usually by a telephone call to the patient, with documentation of a telephone note in the medical record.
After three months, all subjects will return to the clinic for an A1c and BP measure, and for post study surveys. Data collection will include achievement of clinical goals in blood glucose (A1c measure at end of 3 month intervention [+/- 2 weeks] and BP). If enrolled subjects have an available A1c and BP measure recorded in the record at the end of 6 months, we will collect these data to assess longer term effects of the intervention. Patient records will be reviewed for interventions provided to patient (i.e., documenting the process of medication changes, advice provided).
Interview data will be collected from physicians and nurses re: perceptions of use of the data from the device; patient perceptions of the home-device application, and patient use rates of data upload (intervention), and frequency of BG and BP testing both before and during the intervention period (for both intervention and control patients).
The primary outcome measure will be a comparison of A1c at three months following enrollment (i.e., patient met goal of > 0.5% change in A1c or SBP < 130). The proportion of patients who meet the blood glucose / BP goal three months after enrollment will be computed for both the intervention group and the control group. For each group, the denominator will be the number of patients enrolled in that group (and thus were not meeting the recommended goals at the time of enrollment). The numerator will be those patients who meet the recommended goals as determined during an office visit which occurs three months (+/- 14 calendar days) after enrollment.
Changes in care processes will be categorized and described, and related to the patient entered data (daily blood glucose measures).
Physician and nurse perception data will be analyzed using qualitative approaches. Intervention group patient perceptions and satisfaction with the home-device application will be measured using a short survey and analyzed descriptively.
In the intervention group, patient use rates will be calculated to include the percent of readings submitted as the numerator and total expected as denominator (e.g., submitted 70 readings/90 days = 78% use rate).
RN time per week for data review & follow up will be analyzed descriptively to assess the burden of responding to monitoring data.
Data will be collected on the time for enrollment and patient training in order to estimate costs associated with the intervention.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Missouri
-
Columbia, Missouri, Verenigde Staten, 65211
- University of Missouri, Dept. of Family and Community Medicine
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- hemoglobin A1c (A1c) ≥8% OR systolic BP> 130 on last measurement
- on oral medication or insulin
- Type 2 diabetes
- Diabetes and hypertension for at least one year
- using/owns a blood glucose meter (that is compatible with study equipment)
- followed by an attending MD
- private land phone line or computer with internet connection
- enrolled at Family & Community Medicine (FCM) Green Meadows , FCM Woodrail or Fairview General Internal Medicine (GIM) clinic and anticipate receiving primary care for next 12 months from MU primary care
Exclusion Criteria:
- newly diagnosed or Type 1 diabetes
- legally blind
- currently reside in a long-term care facility, including assisted living facility, residential care
- severe cognitive impairment (6-item cognitive screen via recruitment telephone call)
- family/household member enrolled in study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Home Monitoring
100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
|
The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition.
They will upload these measurements using the device to a secure website at least every other day.
Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff.
Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse.
The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
Andere namen:
|
Geen tussenkomst: Usual Care
100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Hemoglobin A1c (HbA1c) or Systolic blood pressure (SBP)
Tijdsspanne: Baseline, 3 months
|
Baseline, 3 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Changes in care (process), abstracted from patient's medical record
Tijdsspanne: 3 months, 6 months following enrollment
|
3 months, 6 months following enrollment
|
Patient-entered device data
Tijdsspanne: All data over three months
|
All data over three months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: David Mehr, MD, University of Missouri, School of Medicine
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1095618
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Home monitoring
-
National University, SingaporeNational University Hospital, SingaporeVoltooid
-
Mayo ClinicSnap40 Ltd.VoltooidOp afstand monitorenVerenigde Staten
-
Rush University Medical CenterUniversity of Illinois at Chicago; Michigan State UniversityActief, niet wervendFysieke activiteitVerenigde Staten
-
Kuopio University HospitalWervingHartoperatieFinland
-
Stryker InstrumentsVoltooidAnesthesie, generaalVerenigde Staten
-
University of WashingtonWerving
-
University Hospital, GhentUniversity GhentBeëindigd
-
DIAMPARKWeprom; Digital Medical HubNog niet aan het werven
-
Pacific Edge LimitedWervingUrotheliale blaaskankerVerenigde Staten
-
University of AberdeenNHS GrampianVoltooidTraumatische hersenschadeVerenigd Koninkrijk